Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Icosavax, Inc.

http://www.icosavax.com/

Latest From Icosavax, Inc.

Ventus Raises $100m To Take First Novel Compounds Into Clinic

Ventus raised $60m in series A venture capital 10 months ago when it had just one technology platform. It now has two platforms, five drug development programs and $100m in series B cash.

Financing Innovation

Icosavax Raises $100m To Take RSV, COVID-19 Vaccines Into The Clinic

The company doubled its series A total of $51m to not only test its coronavirus and RSV candidates, but to also advance a vaccine targeting both RSV and hMPV for pneumonia prevention in elderly adults.

Financing Vaccines

Finance Watch: Billions In And Billions Out In Venture Capital Fundraising

Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.

Financing StartUps and SMEs

Coronavirus Update: Europe To Add Pfizer/BioNTech To COVID-19 Vaccines Supply Roster

Companies in talks with EU authorities for the supply of at least 200 million initial doses of their mRNA vaccine. Plus, other new partnerships around the world and an India pause for AstraZeneca's contender in line with global decision.

Companies Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register